Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas
© Field et al; licensee BioMed Central Ltd. 2008
Received: 18 March 2008
Accepted: 19 May 2008
Published: 19 May 2008
We have used a mouse model based on overexpression of c-Myc in B cells genetically engineered to be self-reactive to test the hypothesis that farnesyl transferase inhibitors (FTIs) can effectively treat mature B cell lymphomas. FTIs are undergoing clinical trials to treat both lymphoid and non-lymphoid malignancies and we wished to obtain evidence to support the inclusion of B cell lymphomas in future trials.
We report that two FTIs, L-744,832 and SCH66336, blocked the growth of mature B cell lymphoma cells in vitro and in vivo. The FTI treatment affected the proliferation and survival of the transformed B cells to a greater extent than naïve B cells stimulated with antigen. In syngeneic mice transplanted with the transgenic lymphoma cells, L-744,832 treatment prevented the growth of the tumor cells and the morbidity associated with the resulting lymphoma progression. Tumors that arose from transplantation of the lymphoma cells regressed with as little as three days of treatment with L-744,832 or SCH66336. Treatment of these established lymphomas with L-744,832 for seven days led to long-term remission of the disease in approximately 25% of animals.
FTI treatment can block the proliferation and survival of self-reactive transformed B cells that overexpress Myc. In mice transplanted with mature B cell lymphomas, we found that FTI treatment led to regression of disease. FTIs warrant further consideration as therapeutic agents for mature B cell lymphomas and other lymphoid tumors.
We have tested farnesyl transferase inhibitors (FTIs) using a mouse model of mature B cell lymphoma to determine if these drugs may be useful in treating similar lymphoid cancers. Although FTIs were originally developed to block the activation of the Ras family of oncogenes, they are also effective in blocking the growth of tumor cells that do not contain mutations at any of the Ras alleles . By blocking the normal processing and subcellular targeting of most farnesylated proteins in the cell, FTI treatment can have many effects. This is due to the large number of farnesylated proteins present, including proteins of the Rho family that are known to mediate antigen receptor signaling in B cells. We therefore chose to test the efficacy of FTIs against our murine B cell lymphoma model, even though there is presently no evidence that activation of Ras plays a role in genesis of the tumors.
The two FTIs that we tested are L-744,832 and SCH66336 (Sarasar, lonafarnib). Developed by Merck, L-744,832 is a peptidomimetic competitive inhibitor of farnesyl transferase that blocks the binding of CAAX peptide substrates. L-744,832 has been shown to block the growth of a variety of tumor cell lines in vitro [2–4], nude mouse xenografts of human tumor cell lines , and mouse tumor models [6–11]. SCH66336 was developed by Schering Plough, completed Phase I clinical trials [12–14], and is currently in Phase II  and Phase III clinical trials. In vitro, SCH66336 has been shown to cause cell death in tumor cell lines [16–18]. Preclinical studies demonstrated that SCH66336 is orally bioavailable and could block the growth of human tumor cells in mouse xenografts  and of mouse tumor cells in transgenic models [17, 19–21]. The efficacy of L-744,832 and SCH66336 does not appear to correlate with the expression of activated Ras protein in either human or murine tumors. Although these two FTIs have been tested in other preclinical models , the efficacy of this class of drugs has not been examined in clinical trials with B cell lymphoma patients.
Certain lymphoid malignancies are sensitive to FTI treatment , suggesting that FTIs can affect the proliferation or survival signaling pathways in lymphocytes. The growth of large cleaved cell lymphomas in transgenic mice expressing an N-Ras oncogene driven by the MMTV promoter can be prevented by SCH66336 treatment . Transformed lymphocytes from T cell ALL patients activate cell death when treated with the FTI R115777 in vitro . In addition to their effects on cancer cells, FTIs have also been shown to affect normal lymphocyte signaling. T cell proliferation stimulated by antigen receptor activation can be blocked by the FTIs cinnamaldehyde  and A-228839 . The dual prenylation inhibitor, L-778,123, which blocks both farnesylation and geranylgeranylation, blocks T cell proliferation activated either by antigen receptor-stimulation or by interleukin-2 (IL-2), without affecting IL-2-mediated survival . Statins, which indirectly affect farnesylation and geranylgeranylation through mevalonate biosynthesis, are also known to have immunomodulatory effects .
We have used a mouse model in which the overexpression of the proto-oncogene c-Myc creates a breach of tolerance in B cells . The self-reactive B cells in these mice generate a mature B cell lymphoma that closely resembles Burkitt's lymphoma in humans . The mice express three transgenes: (A) the oncogene c-Myc expressed from the Eμ immunoglobulin (Ig) heavy chain promoter, (B) the pre-rearranged Ig heavy and light chains specific for hen egg lysozyme (HEL) expressed from the endogenous Ig promoter, and (C) secreted HEL expressed from a metallothionine promoter. The majority of B cells in the Eμ-Myc/BCRHEL/HEL transgenic mice express only BCRHEL IgM on their surface and are specific for the self-antigen, HEL. Tolerance to this self-antigen is overcome by the over-expression of c-Myc in these cells  and the resulting autoreactive B cells are hyperproliferative and form tumors in the lymph nodes and spleen. The lymphoma phenotype occurs in 100% of the Eμ-Myc/ BCRHEL/HEL transgenic mice with a median latency of 8 weeks . The tumors can be transplanted into unmanipulated C57BL/6 mice and the transplant recipients uniformly develop tumors after 3–4 weeks that appear identical to those in the transgenic donors. This transgenic mouse line is similar to other lymphoma models that overexpress c-Myc [31–34], except for context of overexpression, in autoreactive B cells. Antigen receptor activation may be similarly involved in tumorigenesis in certain human lymphoid malignancies .
The development of the Eμ-Myc/BCRHEL/HEL mice permits preclinical testing in this model in an effort to ascertain whether clinical trials of FTIs on mature B cell lymphomas, such as Burkitt's lymphoma, might be in order. In this report, we have demonstrated that FTIs can disrupt the growth and survival pathways in the murine tumor cells. Mice with transplanted tumors showed responses to either FTI, demonstrating effectiveness in vivo of this class of drug against this malignant B cell lymphoma. These preclinical results may have important implications for the treatment of B cell lymphomas in humans, particularly those whose proliferation or survival are dependent on antigen activation.
Mouse B cell lymphoma cells are sensitive to L-744,832 in vitro
Proliferation of the mouse lymphoma cells can be blocked by the FTI, L-744,832. At relatively low concentrations of this drug (0.4 μM, Figure 1, panels c and h), there was no antiproliferative effect on either nontransformed or tumor B cells. At 4 μM L-744,832, a slight effect was seen on the nontransformed B cells (Figure 1, panel d), but the proliferation of the tumor cells was almost completely blocked (Figure 1, panel i). At a concentration of L-744,832 that was not likely to be pharmacologically relevant (40 μM, panels e and j), the proliferation of both cell types was almost completely blocked. From these data, we concluded that L-744,832 prevented the proliferation of the mouse lymphoma cells in vitro and that, under these conditions, it had a greater effect on the tumor cells than on the proliferation of activated, non-transformed B cells stimulated by antigen receptor and CD40 activation.
Efficacy of L-744,832 in vivo
In this experiment, four mice in each group were treated once daily with 625 μg of L-744,832 (~40 mg/kg) intravenously starting the day after tumor transplantation and four mice were left untreated. Daily administration of L-744,832 prevented the transplanted tumors from causing splenomegaly in recipient mice (Figure 2A). Treatment of the wild-type mice also resulted in a small, but significant, decrease in the number of isolated splenocytes and the numbers of viable cells isolated are similar for the two groups of FTI-treated mice.
Figures 2B and 2C show the results from a separate experiment where the recipients were not treated immediately after transplantation of the tumor. Transplant recipients either were treated for 7 days beginning 21 days after transplantation (L744 × 7), when enlarged lymph nodes were visible upon external examination, or were treated for 3 days beginning 24 days after transplantation (L744 × 3), when the mice were beginning to show debilitation due to the lymphomas. The mice were then treated with L-744,832 as above, or left untreated, for comparison. The administration of L-744,832 for either 7 or 3 days caused a large reduction in the size of the spleen (Figure 2B), as well as the lymph nodes and thymi (data not shown) and a corresponding drop in the number of cells isolated from the spleen (Figure 2C). The treated mice became more active and resumed grooming behavior within two days of the start of treatment. Similar results were observed in all four experiments using L-744,832. Together, these experiments show that L-744,832 can prevent mature B cell lymphomas from becoming established in mice and can cause established tumors to regress.
Efficacy of SCH66336 in vivo
Flow cytometry analysis of lymphocytes from FTI-treated mice
Absolute number of viable B cells and T cells after L-744,832 treatment
B: 8.3 ± 4.4 × 105
B: 3.8 ± 0.8 × 107
B: 4.0 ± 3.2 × 105
T: 2.5 ± 1.2 × 106
T: 2.5 ± 0.2 × 107
T: 3.8 ± 1.9 × 107
L744 × 28 Wild-type
B: 9.9 ± 2.8 × 105
B: 1.4 ± 0.8 × 107
B: 1.3 ± 0.6 × 105
T: 1.6 ± 0.9 × 106
T: 9.0 ± 0.5 × 106
T: 1.8 ± 0.7 × 107
B: 2.0 ± 2.5 × 107
B: 1.8 ± 1.0 × 108
B: 7.4 ± 5.9 × 107
T: 4.2 ± 3.9 × 106
T: 4.0 ± 5.4 × 107
T: 2.3 ± 2.1 × 107
L744 × 28 Transplant
B: 2.3 ± 0.8 × 105
B: 7.6 ± 2.9 × 106
B: 9.4 ± 6.6 × 104
T: 4.8 ± 1.3 × 105
T: 5.6 ± 2.4 × 106
T: 9.2 ± 0.8 × 105
L744 × 7 Transplant
B: 2.9 ± 0.7 × 105
B: 1.0 ± 0.4 × 107
B: 5.9 ± 1.9 × 105
T: 5.7 ± 1.2 × 105
T: 6.5 ± 3.2 × 106
T: 9.2 ± 1.9 × 105
Analysis of residual tumor levels following FTI treatment
Sustained remissions of B cell lymphomas with brief L-744,832 treatment
In the second experiment (Figure 7B), the untreated tumor recipients showed visible signs of tumor at 3 weeks and had to be euthanized between 3 and 6 weeks. Ten other tumor recipient mice were treated with L-744,832 starting 21 days after transplantation and 5 of these mice died during treatment, apparently as a result of the treatment. FTI treatment in these 5 mice caused their condition to worsen rapidly and death typically occurred within an hour of the first or second drug administration. Similar acute reactions to FTI treatment were observed in other mice with large tumors (data not shown). These adverse reactions were not as severe in mice that did not receive tumor transplants or in mice that were treated before large tumors were present. This observation is consistent with L-744,832 treatment causing tumor lysis syndrome in mice with a large tumor burden, similar to what is seen in human Burkitt's lymphoma patients treated with current chemotherapy treatment . Tumor lysis syndrome is typically managed effectively in at-risk B cell lymphoma patients . Of the remaining 5 mice, 3 had temporary remissions and later developed large lymphomas, becoming moribund between 8 and 15 weeks after treatment. The lymphadenopathy did not return in the remaining 2 treated mice and they remained healthy 26 weeks after treatment when they were euthanized, showing no evidence of splenomegaly or lymphadenopathy. From these two experiments, combined, we found that 40% (6/15) of the mice died as a possible effect of L-744,832 treatment, and of the mice that survived initial treatment, 33% (3/9) showed long term recovery with no evidence of lymphoma.
Selectivity of FTIs for tumor cells
In the mouse lymphoma model used here, two signaling pathways have been manipulated to generate tumor B cells that recognize a self antigen. Continuous antigen receptor stimulation, provided by the co-expression of BCRHEL and HEL, drives B cell proliferation. This would normally lead to cell death or B cell anergy ; however, the over-expression of c-Myc in these autoreactive B cells overcomes tolerance, allowing the tumor cells to survive and hyperproliferate . The cooperation of c-Myc over-expression and antigen receptor signaling in tumorigenesis may be related to the observation that the Myc transcription factor is required for cytokine-dependent survival signaling in lymphocytes . Over-expression of c-Myc in transgenic B cells renders them independent of cytokines for proliferation and survival in vitro . We reasoned that one or more farnesylated proteins were likely to be critical for the antigen receptor or cytokine receptor/Myc signaling pathways. Therefore, inhibition of farnesyl transferase might restore normal regulation to the dysplastic B cells. Our results clearly support this hypothesis and strongly implicate at least one farnesylated protein in either of these two signaling pathways. This result, alone, is hardly surprising, but what we find most interesting is the apparent specificity of the FTI for the tumor B cells compared to nontransformed lymphocytes. When the proliferation of activated B cells and the transformed B cells were compared in vitro, the tumor cells were approximately 10-fold more sensitive to L-744,832 treatment than naïve B lymphocytes stimulated with antigen receptor and CD40 antibodies (Figure 1).
Similar selectivity for tumor cells was observed in vivo. FTI treatment of mice for as little as three days eliminated > 90% of the tumor cells, while only slightly affecting the normal lymphocyte populations in the same mice (Figures 2, 3, and 4). When mice without tumors were treated with L-744,832 for as long as 28 days, no significant changes were seen in the development of cells in the lymphoid lineages (Figure 4), a process that involves antigen receptor signaling during positive and negative selection of immature lymphocytes. This suggests that the tumor B cells are more susceptible to loss of the functional targets of FTIs than normal B cells. There are at least two explanations for the greater sensitivity of the transformed cells. FTIs could suppress lymphocyte activation specifically under conditions of very high antigenic stimulation, as in the case of a self-antigen, or the breach of tolerance by c-Myc over-expression could render the B cells sensitive to the FTI. These possibilities have implications for the possible use of FTIs to treat autoimmune disease or in conditions of alloreactivity.
Further investigation will be necessary to identify the mechanism that FTIs may be affecting in order to exert the biological effects that we observe. Farnesyl transferase is estimated to modify 40 to 50 different proteins in mammalian cells and the critical anti-neoplastic targets of FTI treatment remain unknown [1, 39]. Proteins whose inhibition can mediate anti-cancer effects of FTIs include RhoB  and the centromeric proteins CENP-E and CENP-F ; most likely a combinatorial effect on many farnesylated proteins is necessary for the cytostatic and cytotoxic effects of FTIs .
The demonstration that several different FTIs can block the production of TH1 and TH2 cytokines from T cells in culture  may provide a partial explanation for the effects of these drugs in our experiments. Marks et al. demonstrate that FTI treatment of activated T cell clones blocked the secretion of IL-2, interferon-γ, IL-4, and IL-5. Cytokine signaling plays a critical role in lymphocyte proliferation and survival, as well as establishing tolerance to self antigens . Therefore, it is possible that FTI treatment affects the hyperproliferation of the self-reactive B cells by interfering with cytokine production. However, the overexpression of Myc in the self-reactive B cells studied here presumably substitutes for IL-4 receptor activation and the transgenic B cells do not require IL-4 production for survival and proliferation . Therefore, we view it as unlikely that the Myc-overexpressing B cells would be affected by an FTI-dependent block of IL-4 production. However, FTI treatment may decrease the production of cytokines by the transformed B cells, which may, in turn, affect the regulatory environment surrounding the B cells and help to restore self tolerance to the HEL self antigen.
Comparison to other FTI preclinical studies
FTI treatment has been shown to have anti-tumor activity in several other mouse cancer models. The mature B cell lymphoma studied here is similar to the non-Hodgkin lymphoma studied by R. Mangues, et al., who demonstrated that L-744,832 could prevent the formation of diffuse large B cell splenic lymphomas in mice that expressed an activated N-Ras oncogene under the MMTV promoter . L-744,832 has also been shown to cause regression of mammary and salivary tumors in mice expressing MMTV- v-H-Ras alone , or together with MMTV- c-Myc . Unlike the above transgenic tumor models, the murine lymphoma studied here does not contain an activated Ras transgene but may express a spontaneously activated Ras allele. Such mutations are not commonly found in B cell non-Hodgkin lymphomas in humans , however, we cannot rule out that a spontaneous mutation occurred at one of the Ras alleles during the process of tumorigenesis in our mouse model. FTIs have mixed results with other mouse tumors that are not known to harbor Ras mutations. For example, the mammary tumors in MMTV- c-Neu mice do not respond to L-744,832 , but the pre-B-cell leukemia in BCR/Abl transgenic mice regressed upon treatment with SCH66336 . Our results are consistent with other models that do not use Ras mutations as an initiating tumorigenic event but have shown that FTI treatment can still effectively block tumor growth.
Implications for treatment of human B cell lymphomas
Our preclinical results with this mouse lymphoma model indicate that patients with mature B cell lymphomas should be considered for inclusion in FTI clinical trials. One of the important features of this mouse model is the self-reactivity of the transformed B cells. Although FTIs do not appear to block proliferation of nontransformed B cells in response to antigen receptor stimulation, these drugs were able to block proliferation and induce cell death in the self-reactive transformed B cells. Antigen receptor activation by self or environmental antigens may contribute the generation of certain B cell malignancies in humans . Recognition of autoantigens or foreign antigens from a chronic infection appears to be an important feature of a substantial fraction of B cell chronic lymphocytic leukemias [47, 48], follicular lymphomas , and certain other leukemias and lymphomas . We suggest that FTIs may be able to block the proliferation of BCR-expressing B cell lymphomas by interfering with the antigen receptor and/or cytokine signaling pathways within the transformed cells.
The lymphoma in the mice used in this study most closely resembles Burkitt's lymphoma, and we propose that FTIs might be a useful addition to the chemotherapy for this cancer. The Raji Burkitt's lymphoma cell line has been shown to be sensitive to a geranylgeranyl transferase inhibitor and to lovastatin but less sensitive to an FTI . Together with our results, this suggests that both FTIs and geranylgeranyl transferase inhibitors should be investigated as possible Burkitt's lymphoma treatments. Initial clinical trials using FTIs focused on cancers that were likely to harbor activating Ras mutations, such as pancreatic cancer. However, subsequent experience has led to the inclusion of many additional patient groups in FTI clinical trials. For example, SCH66336 is undergoing a phase III clinical trial on myelodysplastic syndrome and chronic myelomonocytic leukemia (Study ID P02978). However, mature B cell lymphomas, such as Burkitt's, are not specifically targeted in any of the current FTI clinical trials, perhaps because of the high success rate of current therapies for Burkitt's lymphoma.
Treatment of Burkitt's lymphoma typically involves a combination of chemotherapies: cyclophosphamide, etoposide, vincristine, bleomycin, doxorubicin, methotrexate, and prednisone [36, 51]. Recent evidence has emerged that the anti-CD20 antibody Rituximab may increase the efficacy of treatment in Burkitt's lymphoma, as it does for other mature B cell lymphomas that express CD20 . Although the aggressive combination therapy leads to long-term remission in most patients, at least 20% will relapse within five years and many patients are not able to complete this regimen due to severe side effects. In addition, success rates are considerably lower in older adults and in developing countries where Burkitt's lymphoma is most common . The addition of an FTI to this treatment, possibly in combination with Rituximab, could increase the success rate, allow comparable success with less toxic chemotherapies, or allow more effective treatment of relapsing or refractory cases. Importantly, in regions of the world where Burkitt's lymphoma is most common, conventional treatments are less successful and an orally effective FTI could, in combination with other treatment, have a positive effect on the outcome of this disease.
Using an Eμ-Myc/BCRHEL/HEL transgenic mouse model of a mature B cell lymphoma, we found that FTI treatment could block the hyperproliferation and survival of this lymphoma in vitro and in vivo. Specifically, we showed that proliferation in culture of the transformed B cells from the transgenic mice was more sensitive to L-744,832 treatment than nontransformed activated B cells. In mice we showed that either L-744,832 or SCH66336 treatment caused a rapid loss of tumor cells transplanted from a transgenic mouse. Treatment with L-744,832 for seven days resulted in long term remissions from disease in one third of mice that survived treatment. These results suggest that FTIs should be considered as adjuncts for combination therapies or treatments for refractory cases in patients with mature B cell lymphomas, including Burkitt's lymphoma and other lymphomas that may be dependent on antigen receptor activation. It would be particularly interesting to see if FTI treatment would be effective when combined with Rituximab, an anti-CD20 antibody that can be very effective at treating certain B cell lymphomas.
Eμ-Myc/BCRHEL/HEL transgenic mice have been previously described . Eμ-Myc transgenic mice that overexpress c-Myc in B cells after the Pre/Pro-B cell stage of development  were obtained from The Jackson Laboratory (Bar Harbor, ME). BCRHEL transgenic mice that expressed a pre-rearranged, HEL-specific B cell receptor from the endogenous Ig promoter  were kindly provided by Jason Cyster (University of California, San Francisco). The HEL transgenic mice that expressed secreted HEL from a metallothionine promoter  were also provided by Jason Cyster. Mice were maintained on a C57BL/6 background and genotyped by PCR as previously described [38, 53, 54]. Eμ-Myc/BCRHEL/HEL transgenic mice were obtained by crossing Eμ-Myc mice with mice heterozygous for both BCRHEL and HEL transgenes. All mice were maintained humanely according to protocols approved by the Bucknell University Institutional Animal Care and Use Committee or the UCSF Committee on Animal Research.
Lymphomas were transplanted by removing the spleen and three pairs of lymph nodes (inguinal, axillary, and brachial) from an Eμ-Myc/BCRHEL/HEL transgenic mouse with externally evident lymphoma. Single cell suspensions were prepared separately from spleens and the lymph nodes by macerating organs through a 60 μm mesh screen (Sigma, St. Louis, MO). Red blood cells were lysed using 17 mM Tris, pH 7.65, 135 mM NH4Cl buffer and the remaining splenocytes and lymphocytes were resuspended in complete RPMI media (RPMI 1640 with L-glutamine, penicillin/streptomycin, non-essential amino acids, 2 mM HEPES, 2 mM sodium pyruvate, 10 mM β-mercaptoethanol (all from Invitrogen, Grand Island, NY), and 10% heat-inactivated fetal bovine serum (HyClone, Logan, UT)). Cells were counted using a hemocytometer and Trypan blue staining (Sigma). Cells were washed three times with Hank's Buffered Salt Solution (HBSS, Invitrogen) and each C57BL/6 recipient mouse was intravenously injected with 5 × 105 each of cells from the lymph node and spleen.
Farnesyl Transferase Inhibitors
L-744,832 (BIOMOL, Plymouth Meeting, PA) was dissolved in HBSS at 2.5 mg/ml and filtered through a 0.2 μm syringe filter for sterilization. Aliquots were frozen at -20°C and used within one month. Mice were treated with L-744,832 by tail vein injection of 0.25 ml once daily. SCH66336 was generously provided by Robert Bishop (Schering Plough Research Institute, Kenilworth, NJ). SCH66336 was dissolved in 20% (w/v) hydroxypropyl-β-cyclodextrin (Sigma) in HBSS at 6.25 mg/ml and filtered through a 0.2 μm syringe filter . Mice were treated with SCH66336 by oral gavage with 0.25 ml every 10 to 14 hours. SCH66336 aliquots were frozen and stored at -20°C.
Cell proliferation was measured in culture by labeling with the dye 5-(6)-carboxyfluorescein diacetate, succinimidyl ester (CFSE; Invitrogen). Splenocytes were isolated from either a BCRHEL transgenic mouse or a moribund Eμ-Myc/BCRHEL/HEL transgenic mouse as described above. T cells were depleted using anti-Thy 1.2 paramagnetic beads as described by the manufacturer (Invitrogen). Cells were resuspended at 5 × 106 cells/ml in HBSS and labeled for 5 minutes at room temperature by the addition of an equal volume of 1.0 μM CFSE. The labeling reaction was quenched by the addition of 2 volumes of fetal bovine serum, further diluted with complete RPMI, and cells were then washed three times with complete RPMI. Cells were then placed in culture at 37°C in 5% CO2 at 5 × 105 cells/ml in complete RPMI with 2 μg/ml goat anti- mouse IgM, μ-specific (Jackson Immunoresearch, West Grove, PA), 1 μg/ml anti-mouse CD40 (BD Biosciences, San Diego, CA), and L-744,832, as indicated. A Becton Dickinson FACScan flow cytometer was used to measure proliferation after 3 days. Viable cells were gated based on forward and side scatter. Between 2500 and 10,000 viable cells were analyzed for each sample by measuring the CFSE fluorescence associated with each cell.
Single cell suspensions from the lymph nodes, spleen, or thymus of each mouse were prepared as described above. Cells were resuspended in FACS Buffer and incubated with anti-CD16/CD32 (BD Biosciences) to block Fc receptors. Cells were then labeled, as indicated, with fluorescent antibodies to B220, Thy 1.2, or IgMa (BD Biosciences) diluted 1:50 with FACS Buffer. Unbound antibody was removed by washing with FACS Buffer and cells were fixed with 1% paraformaldehyde (Sigma) in HBSS. Viable cells were gated based on forward and side scatter. For measurement of absolute cell numbers, a Coulter Counter (Beckman Coulter, Fullerton, CA) was used to measure cell density and, separately, a sample was labelled with 7-aminoactinomycin D (7AAD; Invitrogen) and analyzed by flow cytometry as recommended by the manufacturer to determine cell viability.
This work was supported by the Damon Runyon/Walter Winchell Cancer Research Fund (to KAF), the Swanson Research Fellowship (to KAF), a Merck Fellowship of the Life Sciences Research Foundation (to YR), the G. W. Hooper Research Foundation (to JMB), and National Cancer Institute grant number CA44338 (to JMB). We thank Jason Cyster (UCSF) and Robert Bishop (Schering-Plough Research Institute) for generously providing materials. We thank Anthony Defranco (UCSF) and David Holowka (Cornell University) for critically reading the manuscript.
- Cox AD, Der CJ: Farnesyltransferase inhibitors and cancer treatment: targeting simply Ras?. Biochim Biophys Acta. 1997, 1333 (1): F51-71.PubMedGoogle Scholar
- Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Res. 1995, 55 (22): 5302-5309.PubMedGoogle Scholar
- Feldkamp MM, Lau N, Guha A: Growth inhibition of astrocytoma cells by farnesyl transferase inhibitors is mediated by a combination of anti-proliferative, pro-apoptotic and anti-angiogenic effects. Oncogene. 1999, 18 (52): 7514-7526. 10.1038/sj.onc.1203105View ArticlePubMedGoogle Scholar
- van Golen KL, Bao L, DiVito MM, Wu Z, Prendergast GC, Merajver SD: Reversion of RhoC GTPase-induced inflammatory breast cancer phenotype by treatment with a farnesyl transferase inhibitor. Mol Cancer Ther. 2002, 1 (8): 575-583.PubMedGoogle Scholar
- Sirotnak FM, Sepp-Lorenzino L, Kohl NE, Rosen N, Scher HI: A peptidomimetic inhibitor of ras functionality markedly suppresses growth of human prostate tumor xenografts in mice. Prospects for long-term clinical utility. Cancer Chemother Pharmacol. 2000, 46 (1): 79-83. 10.1007/s002800000126View ArticlePubMedGoogle Scholar
- Kohl NE, Omer CA, Conner MW, Anthony NJ, Davide JP, deSolms SJ, Giuliani EA, Gomez RP, Graham SL, Hamilton K: Inhibition of farnesyltransferase induces regression of mammary and salivary carcinomas in ras transgenic mice. Nat Med. 1995, 1 (8): 792-797. 10.1038/nm0895-792View ArticlePubMedGoogle Scholar
- Barrington RE, Subler MA, Rands E, Omer CA, Miller PJ, Hundley JE, Koester SK, Troyer DA, Bearss DJ, Conner MW, Gibbs JB, Hamilton K, Koblan KS, Mosser SD, O'Neill TJ, Schaber MD, Senderak ET, Windle JJ, Oliff A, Kohl NE: A farnesyltransferase inhibitor induces tumor regression in transgenic mice harboring multiple oncogenic mutations by mediating alterations in both cell cycle control and apoptosis. Mol Cell Biol. 1998, 18 (1): 85-92.PubMed CentralPubMedGoogle Scholar
- Mangues R, Corral T, Kohl NE, Symmans WF, Lu S, Malumbres M, Gibbs JB, Oliff A, Pellicer A: Antitumor effect of a farnesyl protein transferase inhibitor in mammary and lymphoid tumors overexpressing N-ras in transgenic mice. Cancer Res. 1998, 58 (6): 1253-1259.PubMedGoogle Scholar
- Mahgoub N, Taylor BR, Gratiot M, Kohl NE, Gibbs JB, Jacks T, Shannon KM: In vitro and in vivo effects of a farnesyltransferase inhibitor on Nf1-deficient hematopoietic cells. Blood. 1999, 94 (7): 2469-2476.PubMedGoogle Scholar
- Norgaard P, Law B, Joseph H, Page DL, Shyr Y, Mays D, Pietenpol JA, Kohl NE, Oliff A, Coffey RJ, Poulsen HS, Moses HL: Treatment with farnesyl-protein transferase inhibitor induces regression of mammary tumors in transforming growth factor (TGF) alpha and TGF alpha/neu transgenic mice by inhibition of mitogenic activity and induction of apoptosis. Clin Cancer Res. 1999, 5 (1): 35-42.PubMedGoogle Scholar
- Omer CA, Chen Z, Diehl RE, Conner MW, Chen HY, Trumbauer ME, Gopal-Truter S, Seeburger G, Bhimnathwala H, Abrams MT, Davide JP, Ellis MS, Gibbs JB, Greenberg I, Koblan KS, Kral AM, Liu D, Lobell RB, Miller PJ, Mosser SD, O'Neill TJ, Rands E, Schaber MD, Senderak ET, Oliff A, Kohl NE: Mouse mammary tumor virus-Ki-rasB transgenic mice develop mammary carcinomas that can be growth-inhibited by a farnesyl:protein transferase inhibitor. Cancer Res. 2000, 60 (10): 2680-2688.PubMedGoogle Scholar
- Adjei AA, Erlichman C, Davis JN, Cutler DL, Sloan JA, Marks RS, Hanson LJ, Svingen PA, Atherton P, Bishop WR, Kirschmeier P, Kaufmann SH: A Phase I trial of the farnesyl transferase inhibitor SCH66336: evidence for biological and clinical activity. Cancer Res. 2000, 60 (7): 1871-1877.PubMedGoogle Scholar
- Eskens FA, Awada A, Cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M: Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors. J Clin Oncol. 2001, 19 (4): 1167-1175.PubMedGoogle Scholar
- Khuri FR, Glisson BS, Kim ES, Statkevich P, Thall PF, Meyers ML, Herbst RS, Munden RF, Tendler C, Zhu Y, Bangert S, Thompson E, Lu C, Wang XM, Shin DM, Kies MS, Papadimitrakopoulou V, Fossella FV, Kirschmeier P, Bishop WR, Hong WK: Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors. Clin Cancer Res. 2004, 10 (9): 2968-2976. 10.1158/1078-0432.CCR-03-0412View ArticlePubMedGoogle Scholar
- Sharma S, Kemeny N, Kelsen DP, Ilson D, O'Reilly E, Zaknoen S, Baum C, Statkevich P, Hollywood E, Zhu Y, Saltz LB: A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan. Ann Oncol. 2002, 13 (7): 1067-1071. 10.1093/annonc/mdf173View ArticlePubMedGoogle Scholar
- Glass TL, Liu TJ, Yung WK: Inhibition of cell growth in human glioblastoma cell lines by farnesyltransferase inhibitor SCH66336. Neuro-oncol. 2000, 2 (3): 151-158. 10.1215/15228517-2-3-151PubMed CentralPubMedGoogle Scholar
- Peters DG, Hoover RR, Gerlach MJ, Koh EY, Zhang H, Choe K, Kirschmeier P, Bishop WR, Daley GQ: Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001, 97 (5): 1404-1412. 10.1182/blood.V97.5.1404View ArticlePubMedGoogle Scholar
- Ganguly AK, Doll RJ, Girijavallabhan VM: Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336. Curr Med Chem. 2001, 8 (12): 1419-1436.View ArticlePubMedGoogle Scholar
- Liu M, Bishop WR, Nielsen LL, Bryant MS, Kirschmeier P: Orally bioavailable farnesyltransferase inhibitors as anticancer agents in transgenic and xenograft models. Methods Enzymol. 2001, 333: 306-318.View ArticlePubMedGoogle Scholar
- Liu M, Bryant MS, Chen J, Lee S, Yaremko B, Lipari P, Malkowski M, Ferrari E, Nielsen L, Prioli N, Dell J, Sinha D, Syed J, Korfmacher WA, Nomeir AA, Lin CC, Wang L, Taveras AG, Doll RJ, Njoroge FG, Mallams AK, Remiszewski S, Catino JJ, Girijavallabhan VM, Bishop WR: Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice. Cancer Res. 1998, 58 (21): 4947-4956.PubMedGoogle Scholar
- Reichert A, Heisterkamp N, Daley GQ, Groffen J: Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001, 97 (5): 1399-1403. 10.1182/blood.V97.5.1399View ArticlePubMedGoogle Scholar
- Brunner TB, Hahn SM, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ: Farnesyltransferase inhibitors: an overview of the results of preclinical and clinical investigations. Cancer Res. 2003, 63 (18): 5656-5668.PubMedGoogle Scholar
- Harousseau JL: Farnesyltransferase inihibitors in hematologic malignancies. Blood Rev. 2007, 21 (4): 173-182. 10.1016/j.blre.2006.12.001View ArticlePubMedGoogle Scholar
- Goemans BF, Zwaan CM, Harlow A, Loonen AH, Gibson BE, Hahlen K, Reinhardt D, Creutzig U, Heinrich MC, Kaspers GJ: In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets. Blood. 2005, 106 (10): 3532-3537. 10.1182/blood-2005-04-1640View ArticlePubMedGoogle Scholar
- Koh WS, Yoon SY, Kwon BM, Jeong TC, Nam KS, Han MY: Cinnamaldehyde inhibits lymphocyte proliferation and modulates T-cell differentiation. Int J Immunopharmacol. 1998, 20 (11): 643-660. 10.1016/S0192-0561(98)00064-2View ArticlePubMedGoogle Scholar
- Si MS, Ji P, Tromberg BJ, Lee M, Kwok J, Ng SC, Imagawa DK: Farnesyltransferase inhibition: a novel method of immunomodulation. Int Immunopharmacol. 2003, 3 (4): 475-483. 10.1016/S1567-5769(02)00278-3View ArticlePubMedGoogle Scholar
- Si MS, Reitz BA, Borie DC: Inhibition of lymphocyte activation and function by the prenylation inhibitor L-778, 123. Invest New Drugs. 2005, 23 (1): 21-29. 10.1023/B:DRUG.0000047102.26698.08View ArticlePubMedGoogle Scholar
- Greenwood J, Steinman L, Zamvil SS: Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol. 2006, 6 (5): 358-370. 10.1038/nri1839View ArticlePubMedGoogle Scholar
- Refaeli Y, Field KA, Turner BC, Trumpp A, Bishop JM: The protooncogene MYC can break B cell tolerance. Proc Natl Acad Sci U S A. 2005, 102 (11): 4097-4102. 10.1073/pnas.0409832102PubMed CentralView ArticlePubMedGoogle Scholar
- Refaeli Y, Young RM, Turner BC, Duda J, Field KA, Bishop JM: The B-cell antigen receptor and overexpression of MYC can cooperate in the genesis of B-cell lymphomas. PLoS Biology in press.
- Kovalchuk AL, Qi CF, Torrey TA, Taddesse-Heath L, Feigenbaum L, Park SS, Gerbitz A, Klobeck G, Hoertnagel K, Polack A, Bornkamm GW, Janz S, Morse HC: Burkitt lymphoma in the mouse. J Exp Med. 2000, 192 (8): 1183-1190. 10.1084/jem.192.8.1183PubMed CentralView ArticlePubMedGoogle Scholar
- Park SS, Kim JS, Tessarollo L, Owens JD, Peng L, Han SS, Tae Chung S, Torrey TA, Cheung WC, Polakiewicz RD, McNeil N, Ried T, Mushinski JF, Morse HC, Janz S: Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 2005, 65 (4): 1306-1315. 10.1158/0008-5472.CAN-04-0268View ArticlePubMedGoogle Scholar
- Zhu D, Qi CF, Morse HC, Janz S, Stevenson FK: Deregulated expression of the Myc cellular oncogene drives development of mouse "Burkitt-like" lymphomas from naive B cells. Blood. 2005, 105 (5): 2135-2137. 10.1182/blood-2004-07-2573View ArticlePubMedGoogle Scholar
- Wang J, Boxer LM: Regulatory elements in the immunoglobulin heavy chain gene 3'-enhancers induce c-myc deregulation and lymphomagenesis in murine B cells. J Biol Chem. 2005, 280 (13): 12766-12773. 10.1074/jbc.M412446200View ArticlePubMedGoogle Scholar
- Kuppers R: Mechanisms of B-cell lymphoma pathogenesis. Nat Rev Cancer. 2005, 5 (4): 251-262. 10.1038/nrc1589View ArticlePubMedGoogle Scholar
- Evens AM, Gordon LI: Burkitt's and Burkitt-like lymphoma. Curr Treat Options Oncol. 2002, 3 (4): 291-305. 10.1007/s11864-002-0029-9View ArticlePubMedGoogle Scholar
- Cairo MS, Bishop M: Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004, 127 (1): 3-11. 10.1111/j.1365-2141.2004.05094.xView ArticlePubMedGoogle Scholar
- Goodnow CC, Crosbie J, Adelstein S, Lavoie TB, Smith-Gill SJ, Brink RA, Pritchard-Briscoe H, Wotherspoon JS, Loblay RH, Raphael K: Altered immunoglobulin expression and functional silencing of self-reactive B lymphocytes in transgenic mice. Nature. 1988, 334 (6184): 676-682. 10.1038/334676a0View ArticlePubMedGoogle Scholar
- Haluska P, Dy GK, Adjei AA: Farnesyl transferase inhibitors as anticancer agents. Eur J Cancer. 2002, 38 (13): 1685-1700. 10.1016/S0959-8049(02)00166-1View ArticlePubMedGoogle Scholar
- Lebowitz PF, Prendergast GC: Non-Ras targets of farnesyltransferase inhibitors: focus on Rho. Oncogene. 1998, 17 (11 Reviews): 1439-1445. 10.1038/sj.onc.1202175View ArticlePubMedGoogle Scholar
- Ashar HR, James L, Gray K, Carr D, Black S, Armstrong L, Bishop WR, Kirschmeier P: Farnesyl transferase inhibitors block the farnesylation of CENP-E and CENP-F and alter the association of CENP-E with the microtubules. J Biol Chem. 2000, 275 (39): 30451-30457. 10.1074/jbc.M003469200View ArticlePubMedGoogle Scholar
- Tamanoi F, Gau CL, Jiang C, Edamatsu H, Kato-Stankiewicz J: Protein farnesylation in mammalian cells: effects of farnesyltransferase inhibitors on cancer cells. Cell Mol Life Sci. 2001, 58 (11): 1636-1649. 10.1007/PL00000802View ArticlePubMedGoogle Scholar
- Marks RE, Ho AW, Robbel C, Kuna T, Berk S, Gajewski TF: Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level. Blood. 2007, 110 (6): 1982-1988. 10.1182/blood-2006-06-031088PubMed CentralView ArticlePubMedGoogle Scholar
- St Clair EW, Turka LA, Saxon A, Matthews JB, Sayegh MH, Eisenbarth GS, Bluestone J: New reagents on the horizon for immune tolerance. Annu Rev Med. 2007, 58: 329-346. 10.1146/annurev.med.58.061705.145449View ArticlePubMedGoogle Scholar
- Kohl NE, Wilson FR, Thomas TJ, Bock RL, Mosser SD, Oliff A, Gibbs JB: Inhibition of Ras function in vitro and in vivo using inhibitors of farnesyl-protein transferase. Methods Enzymol. 1995, 255: 378-386.View ArticlePubMedGoogle Scholar
- Neri A, Knowles DM, Greco A, McCormick F, Dalla-Favera R: Analysis of RAS oncogene mutations in human lymphoid malignancies. Proc Natl Acad Sci U S A. 1988, 85 (23): 9268-9272. 10.1073/pnas.85.23.9268PubMed CentralView ArticlePubMedGoogle Scholar
- Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, Budman DR, Lichtman SM, Schulman P, Weiselberg LR, Chiorazzi N: Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. J Exp Med. 1989, 169 (1): 255-268. 10.1084/jem.169.1.255View ArticlePubMedGoogle Scholar
- Fais F, Ghiotto F, Hashimoto S, Sellars B, Valetto A, Allen SL, Schulman P, Vinciguerra VP, Rai K, Rassenti LZ, Kipps TJ, Dighiero G, Schroeder HW, Ferrarini M, Chiorazzi N: Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest. 1998, 102 (8): 1515-1525. 10.1172/JCI3009PubMed CentralView ArticlePubMedGoogle Scholar
- Dighiero G, Hart S, Lim A, Borche L, Levy R, Miller RA: Autoantibody activity of immunoglobulins isolated from B-cell follicular lymphomas. Blood. 1991, 78 (3): 581-585.PubMedGoogle Scholar
- van de Donk NW, Schotte D, Kamphuis MM, van Marion AM, van Kessel B, Bloem AC, Lokhorst HM: Protein geranylgeranylation is critical for the regulation of survival and proliferation of lymphoma tumor cells. Clin Cancer Res. 2003, 9 (15): 5735-5748.PubMedGoogle Scholar
- McMaster ML, Greer JP, Greco FA, Johnson DH, Wolff SN, Hainsworth JD: Effective treatment of small-noncleaved-cell lymphoma with high-intensity, brief-duration chemotherapy. J Clin Oncol. 1991, 9 (6): 941-946.PubMedGoogle Scholar
- Attias D, Weitzman S: The efficacy of rituximab in high-grade pediatric B-cell lymphoma/leukemia: a review of available evidence. Curr Opin Pediatr. 2008, 20 (1): 17-22. 10.1097/MOP.0b013e3282f424b0View ArticlePubMedGoogle Scholar
- Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, Palmiter RD, Brinster RL: The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985, 318 (6046): 533-538. 10.1038/318533a0View ArticlePubMedGoogle Scholar
- Hartley SB, Crosbie J, Brink R, Kantor AB, Basten A, Goodnow CC: Elimination from peripheral lymphoid tissues of self-reactive B lymphocytes recognizing membrane-bound antigens. Nature. 1991, 353 (6346): 765-769. 10.1038/353765a0View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.